AbbVie Revenue Rises on Immunology Growth

Core Insights - AbbVie reported higher fourth-quarter revenue driven by growth in its immunology portfolio, particularly from arthritis and Crohn's disease drugs Skyrizi and Rinvoq [1] Revenue Growth - The increase in revenue is attributed to the strong performance of the immunology drugs, which have seen significant demand in the market [1]